Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT03118466
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธMassachusetts general Hospital, Boston, Massachusetts, United States
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT02937285
- Locations
- ๐ซ๐ท
CHU Rennes, Rennes, France
Optimal Treatment Strategy Based on for Pediatric AML
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2016-07-28
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 350
- Registration Number
- NCT02848183
- Locations
- ๐ฐ๐ท
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
๐ฐ๐ทSt. Mary Hospital, Seoul, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 84
- Registration Number
- NCT02728050
- Locations
- ๐บ๐ธ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 700
- Registration Number
- NCT02724163
- Locations
- ๐ฆ๐บ
Monash Children's Hospital, Melbourne, Australia
๐ฆ๐บWomen and Children's Hospital Adelaide, Adelaide, Australia
๐ฆ๐บQueensland Children's Hospital, Brisbane, Australia
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Technische Universitรคt Dresden
- Target Recruit Count
- 280
- Registration Number
- NCT02688140
- Locations
- ๐ฉ๐ช
OSHO study group, Multiple Locations, Germany
๐ฉ๐ชSAL study group, Multiple Locations, Germany
๐ณ๐ฑHOVON study group, Multiple Locations, Netherlands
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 153
- Registration Number
- NCT02632708
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Alison Sehgal, MD, MS
- Target Recruit Count
- 1
- Registration Number
- NCT02631252
- Locations
- ๐บ๐ธ
University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02626338
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธHouston Methodist, Houston, Texas, United States
๐บ๐ธUniversity of Arkansas, Little Rock, Arkansas, United States
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-10-10
- Target Recruit Count
- 39
- Registration Number
- NCT02583893
- Locations
- ๐บ๐ธ
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.